Serum and synovial fluid levels of p40 IL12/23 in spondyloarthropathy patients

Autor: Jean-Pierre Cedoz, Daniel Wendling, Evelyne Racadot
Přispěvatelé: Agents pathogènes et inflammation - UFC (EA 4266) (API), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)
Rok vydání: 2008
Předmět:
Male
Spondyloarthropathy
MESH: Interleukin-17
Osteoarthritis
Gastroenterology
Receptors
Tumor Necrosis Factor
Etanercept
MESH: Antibodies
Monoclonal
0302 clinical medicine
MESH: Osteoarthritis
Synovial Fluid
MESH: Treatment Outcome
MESH: Aged
MESH: Immunoglobulin G
0303 health sciences
MESH: Middle Aged
Interleukin-12 Subunit p40
Interleukin-17
Antibodies
Monoclonal
General Medicine
Middle Aged
MESH: Case-Control Studies
C-Reactive Protein
Treatment Outcome
[SDV.MHEP.RSOA]Life Sciences [q-bio]/Human health and pathology/Rhumatology and musculoskeletal system
Monoclonal
Disease Progression
MESH: Disease Progression
Female
Matrix Metalloproteinase 3
MESH: Spondylarthropathies
medicine.drug
musculoskeletal diseases
Adult
medicine.medical_specialty
Blood Sedimentation
Antibodies
Monoclonal
Humanized
03 medical and health sciences
Rheumatology
Internal medicine
MESH: Synovial Fluid
MESH: C-Reactive Protein
medicine
Adalimumab
Synovial fluid
Humans
MESH: Blood Sedimentation
030304 developmental biology
Aged
030203 arthritis & rheumatology
Ankylosing spondylitis
MESH: Humans
business.industry
Tumor Necrosis Factor-alpha
MESH: Adult
medicine.disease
MESH: Receptors
Tumor Necrosis Factor
MESH: Male
MESH: Matrix Metalloproteinase 3
MESH: Interleukin-12 Subunit p40
MESH: Tumor Necrosis Factor-alpha
Case-Control Studies
Immunoglobulin G
Immunology
Spondylarthropathies
business
MESH: Female
Zdroj: Clinical Rheumatology
Clinical Rheumatology, Springer Verlag, 2009, 28 (2), pp.187-90. ⟨10.1007/s10067-008-1011-0⟩
ISSN: 1434-9949
0770-3198
DOI: 10.1007/s10067-008-1011-0⟩
Popis: International audience; IL-23 is the main inductor in Th17 polarization of naive T cells, inducing IL-17 production. IL-17 has been demonstrated to be elevated in ankylosing spondylitis (AS). The p40 subunit is common to IL-12 and IL-23. We assessed serum and synovial levels of p40 IL12/23 in spondyloarthropathy (SpA) patients and the evolution under anti-TNF. SpA patients fulfilling ESSG criteria were included. Healthy volunteers served as controls. P40 IL12/23 was assessed using Human Quantikine ELISA (R&D Systems), and at the same time, BASDAI, ESR, CRP, IL-17, MMP-3. Patients treated with anti-TNF were evaluated again after 10 weeks of treatment. Statistical analysis used Mann Whitney and correlation tests. Twenty-seven SpA outpatients (20 men), mean age 40.3 years, mean disease duration 10.5 years, HLA B27 positive n = 21, peripheral arthritis n = 8, mean BASDAI 45.7, mean CRP 30.7 mg/l, and 24 controls (12 men), mean age 50.4 years, were included. There is no statistical difference in serum levels of p40IL12/23 between patients (mean 77.8 pg/ml) and controls (103 pg/ml) and between patients with axial and peripheral involvement. Levels were higher in HLA B-27 negative patients (p = 0.02). No statistical correlation was found between p40 IL12/40 serum levels and each of BASDAI, ESR, CRP, serum levels of IL 17, MMP 3. Fourteen AS patients were treated with TNF blockers. Whereas significant reduction in BASDAI, ESR, and CRP were obvious after treatment, there was no significant change in serum level of p40 IL12/23. Mean levels of synovial p40 IL12/23 were higher in SpA patients (n = 6; mean 536 pg/ml) compared to osteoarthritis patients (n = 3; 133 pg/ml) and compared with paired serum SpA levels. These results suggest that serum levels of p40 IL-12/23 may not be considered as a biologic tool of disease activity assessment in SpA patients.
Databáze: OpenAIRE
Externí odkaz: